Recent Updates
Recently added Catalysts
CORT Negative Sentiment Score: 20/100

Corcept Therapeutics Incorporated Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 21, 2026 to Discuss Your Rights – CORT

Key Takeaway: A class action securities fraud lawsuit has been filed against Corcept Therapeutics by Levi & Korsinsky, LLP, on behalf of investors who incurred losses between October 31, 2024 and December 30, 2025. The lawsuit claims that the company made false statements regarding its interactions with the FDA, particularly concerning the effectiveness of relacorilant in treating hypertension. It suggests that Corcept was aware of significant issues that would arise from a potential NDA submission. Investors affected by these claims are encouraged to contact Levi & Korsinsky for legal representation.

Market Sentiment Analysis

CONCERNS & RISKS

  • Corcept Therapeutics is facing a class action lawsuit alleging securities fraud.
  • The FDA has indicated serious concerns about the adequacy of their program for relacorilant.
  • Statements regarding the FDA's interactions and expectations for NDA approval were found to be materially false or misleading.

Full Press Release Details

NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated" or the "Company") (NASDAQ: CORT) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Corcept Therapeutics Incorporated investors who were adversely affected by alleged securities fraud between October 31, 2024 and December 30, 2025. Follow the link below to get more information and be contacted by a member of our team:
CORT investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: According to the filed complaint, defendants made false statements and/or concealed that: In light of the circumstances in which they were made, not false and misleading. In truth, the FDA had told Corcept that it had concerns about the adequacy of the program assessing relacorilant’s effectiveness in treating hypertension in patients with hypercortisolism, including the design of the GRACE study. The FDA had further told Corcept to expect significant issues with the review if Corcept was to submit the NDA. As a result, Defendants’ positive statements concerning their interactions with the FDA and their expectations that the relacorilant NDA would be approved, were materially false or misleading.
WHAT'S NEXT? If you suffered a loss in Corcept Therapeutics Incorporated during the relevant time frame, you have until April 21, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor

Tags

Frequently Asked Questions

What is the lawsuit against Corcept Therapeutics about?

The lawsuit addresses alleged securities fraud impacting investors between October 31, 2024, and December 30, 2025.

Who can participate in the Corcept lawsuit?

Investors who experienced losses in Corcept during the relevant time frame can participate.

Is it costly to join the Corcept class action?

No, class members may receive compensation without any out-of-pocket costs or fees.

What issues did the FDA raise about Corcept's drug?

The FDA expressed concerns regarding the efficacy assessment program for relacorilant.

How can I contact Levi & Korsinsky for the lawsuit?

You can email Joseph E. Levi at jlevi@levikorsinsky.com or call (212) 363-7500.

Last updated: Mar 16, 2026